AbCellera Biologics Inc.

NasdaqGS ABCL

AbCellera Biologics Inc. Shareholders' Equity for the year ending December 31, 2023: USD 1.15 B

AbCellera Biologics Inc. Shareholders' Equity is USD 1.15 B for the year ending December 31, 2023, a -6.56% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

AbCellera Biologics Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 1.23 B, a 20.23% change year over year.
AbCellera Biologics Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 1.03 B, a 23.51% change year over year.
AbCellera Biologics Inc. Shareholders' Equity for the year ending December 31, 2020 was USD 830.51 M, a 8,000.82% change year over year.
AbCellera Biologics Inc. Shareholders' Equity for the year ending December 31, 2019 was USD 10.25 M, a -11.69% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: ABCL

AbCellera Biologics Inc.

CEO	Dr. Carl L.G. Hansen Ph.D.
IPO Date	Dec. 11, 2020
Location	Canada
Headquarters	2215 Yukon Street
Employees	586
Sector	Healthcare
Industries Biotechnology Artificial Intelligence (AI) Big Data Clinical Trials Pharmaceuticals Robotics Vaccines Venture Capital

Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years